MIRA Pharmaceuticals (NASDAQ:MIRA) Posts Quarterly Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) issued its earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports.

MIRA Pharmaceuticals Stock Up 4.8%

Shares of MIRA Pharmaceuticals stock traded up $0.04 during trading hours on Friday, hitting $0.79. The company’s stock had a trading volume of 55,737 shares, compared to its average volume of 131,178. MIRA Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $2.45. The business has a fifty day moving average of $0.89 and a 200 day moving average of $1.03. The company has a market capitalization of $33.03 million, a PE ratio of -0.60 and a beta of 1.54.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new stake in MIRA Pharmaceuticals in the 2nd quarter valued at $27,000. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals during the second quarter worth about $26,000. Two Sigma Investments LP boosted its position in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after buying an additional 25,816 shares during the period. Fifth Third Bancorp purchased a new stake in shares of MIRA Pharmaceuticals in the fourth quarter worth about $30,000. Finally, Geode Capital Management LLC grew its stake in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares in the last quarter. Institutional investors and hedge funds own 35.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded MIRA Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.